The resolution of acute episodes and the prevention of subsequent recurrences during anti-IL-1 therapy support the hypotheses that interleukin-1 is an important mediator of recurrent pericarditis in patients who have evidence of systemic inflammation. The gene discussed is IL1B; the disease is pericarditis.